DOCSLIB.ORG

MT PT No Patent Title Applicant Name Applicant Address MT Filing Date Priority Date Status Abstract 993 Antihypertensive Combina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MT PT No Patent Title Applicant Name Applicant Address MT Filing Date Priority Date Status Abstract 993 Antihypertensive Combina MT PT Patent Title Applicant Name Applicant Address MT Filing Date Priority Date Status Abstract No Bayer Aktiengesellschaft & Filing Date: 5090 Leverkusen West Antihypertensive Combination F.Hoffmann-La Roche & Co. 03/12/1986 Rec Warrant signed on 993 Germany & 4002 Basel, Wef: 04/12/1985 Vide PT 993 Product Aktiengeschaft No. G675271 dt 21/08/1987 Switzerland Attn: SS & Co. 03/12/1986 Filing Date: F.Hoffman Roche + Co. Basel, 22/01/1987 Rec. Warrant signed on 996 Benzazecine Derivatives AKTIENGESELLSCHAFT Switzerland Wef: 23/01/1986 Vide PT 996 G676991 dt 21/08/1987 Att. S S & Co. 22/01/1987 Novo Alle, DK-2880 Filing Date: Novo-Nordisk A/S & Albright Bagsvaerd, Demark & 20/02/1987 Rec: Warrant signed on 997 Protected Enzyme Systems & Wilson Limited Albright & Wilson House, Wef: 20/02/1986 Vide PT 997 G677984 dt 18/10/1988 Attn: SS & Co. Hagley Road West 20/02/1987 Oldbury, Warley, West Midlands, England Novartis AG (Novartis SA), Filing Date: Alpha-Heterocycle substituted (Novartis Inc.) Schwarzwaldallee 215, 06/03/1987 Rec: Warrant signed on 998 Wef: 07/03/1986 Vide PT 998 Tolunitriles Att. S S & Co. 4050 Basel, Switzerland G738323 dt 21/08/1987 06/031987 Compounds having a cognition Patent and Licensing adjuvant action, agents Filing Date: HOECHST Department, Building containing them, and the use 25/03/1987 Warrant signed on 1001 AKTIENGESELLSCHAFT K801, D65926 Frankfurt Wef: N/A Vide PT 1001 thereof for the treatment and Rec: G738376 dt 18/10/1988 Att: Dr G.M. Camilleri am Main, Federal prophylaxis of cognitive 25/03/1987 Republic of Germany dysfunctions. Patent and Licensing Ethylene oxide/propylene oxide Department block copolymers for controlling Building K801 Filing Date: HOECHST foam in liquid pharmaceutical D65926 Frankfurt am 28/05/1987 Rec: Warrant signed on 1002 AKTIENGESELLSCHAFT Wef: N/A Vide PT 1002 formulations, pharmaceutical Main G795946 dt 30/12/1987 Att: Dr G.M. Camilleri formulations, and a process for Federal Republic of 28/05/1987 their preparation. Germany 2-Kanda-Mikura-Cho, Sankei Pharmaceutical B-Lactam compound, method Chiyoda-ku, Tokyo Company Limited & Nippon for preparing the same, Japan 3-25 & Hanazono- Pharmaceutical Filing Date: medicinal composition for Cho, Development Insittute 16/07/1987 Rec: Warrant signed on 1006 bacterially infectious disease Mukawa-machi, Wef: 21/07/1986 Vide PT 1006 Company Limited G850816 dt 18/10/1988 therapy containing the same and Yuufutsu-gun, Att. S S & Co. 16/07/1987 intermediates for synthesis of Hokkaido, Japan the same. Filing Date: Molecular Structure of Diltiazem Piazza Duca D’Aosta 12, 04/11/1987 Rec: Schiapparelli Farmaceutici 1009 Hydrochloride. Milano 20124 G975168 dt Wef: N/A ABANDONED Vide PT 1009 S.p.A Italy 04/11/1987 New Pharmacologically active Filing Date: compounds, methods for the ORION- YHTYMA DY Saunatontunie 1,02200 26/11/1987 Rec: Warrant Signed on 1012 preparation thereof and Wef: 28/11/1986 Vide PT 1012 Att: S S & Co. Espoo, Finland H 000560 dt 18/10/1988 compositions containing the 26/11/1987 same. Substitued aminopropionamides, a process D-6230 Frankfurt am Filing Date: Hoechst Aktiengesellshaft for their preparation, agents Main 80, 09/12/1987 Rec: 1014 Att. Dr G.M Camilleri. Wef: 12/12/1986 WITHDRAWN Vide PT 1014 containing them, and their use, Federal Republic of H 000578 and new intermediates Germany dt 09/12/1987 producted in their preparation. F. Hoffmann La Roche AG Filing Date: Hydrocinnamic Acid Derivatives. 124-184 Attn: S S & Co. 06/07/1988 Warrant signed on 1023 Grezacherstrasse, 4002 Wef: 21/07/1987 Vide PT 1023 Rec: H238167 18/07/1989 Basel, Switzerland dt 06/07/1988 New use of Cathechol-o-methyl Filing Date: transferase (comt) inhibitors and ORION- YHTYMA DY Saunatontunie 1,02200 16/12/1988 Rec: Warrant signed 1031 Wef: 24/12/1987 Vide PT 1031 their physiologically acceptable Att: S S & Co. Espoo, Finland 462511 dt 04/10/1990 salts and Esters. 16/12/1988 Filing Date: Imperial Chemical Industries Imperial Chemical A method for the amplification of 01/08/1989 Rec: Warrant signed on 1043 PLC Attn: Dr T. House, Millbank, London Wef: 28/07/1988 Vide PT 1043 nucleotide sequences. H638957 dt 14/06/1990 Grech SW1P 3JF, England 01/08/1989 Minnesota Mining and Filing Date: Fluorocarbon Elastomers 3M Centre, Saint Paul, Manufacturing Company 18/08/1989 Warrant signed on 1045 crosslinked by ionizing Minnesota 55144-1000, Wef: 29/08/1988 Vide PT 1045 Att. J. Mifsud. Rec: H638977 14/06/1990 Radiation. U.S.A. dt 18/08/1989 Filing Date: 124, Grenzacherstrasse, F. Hoffmann-La Roche AG 30/10/1989 Rec: Warrant signed on 1049 Penicillanic Acid Derivatives Ch-4002 Basel, Wef: 31/10/1988 Vide PT 1049 Attn: S S & Co. H812053 dt 06/11/1990 Switzerland 30/10/1989 Elarges House, Filing Date: 6/12 Elarges Street, Glasco Gravy Limited 16/01/1990 Rec: Warrant signed on 1052 Furan Derivatives London WIY 8DH, Wef: N/A Vide PT 1052 Attn: S S & Co. H813582 dt 06/11/1990 England 16/01/1990 Minnesota Mining and 3M Centre, Saint Paul, Filing Date: Fluoroclastomer Composition Manufacturing Company Minnesota 55144-1000, 24/05/1990 Warrant signed on 1061 with improved Bonding Wef: 22/06/1989 Vide PT 1061 Attn: Mr J. Mifsud U.S.A. Rec: H977738 dt 08/04/1991 Properties 24/05/1990 Filing Date: Plasmids, their construction and 5100 –Aachen, 28/06/1990 Rec: Grunenthal Gmbh Warrant signed on 1063 their use in manufacture of a Federal Republic of J036803 dt Wef: 19/07/1989 Vide PT 1063 Att. Joseph Mifsud. 08/04/1991 plasminogen activator. Germany 28/06/1990 Pholos N.V Filing Date: Process for the continuous De Ruyten Kade 62, A Company of the 12/10/1990 Rec: Warrant signed on 1070 production of high molecular Curacao, Wef: 13/10/1989 Vide PT 1070 Netherlands Antilles J162919 dt 30/06/1991 Weight polyester resin. Netherlands Antilles Att. S S & Co. 12/10/1990 3M Centre, Saint Paul, Filing Date: Minnesota Mining and Minnesota 55144-1000, 05/11/1990 Rec: Warrant signed on 1073 Polymer Blend Composition. Manufacturing Company Wef: 16/11/1989 Vide PT 1073 U.S.A. J162958 dt 30/06/1991 Attn: B&M Patentbureau 05/11/1990 Filing Date: 124 Grenzacherstrasse, F.Hoffman--La Roche AG 15/11/1990 Rec: Warrant signed on 1075 Amino Acid Derivatives. CH-4002 Basel, Wef: 11/12/1989 Vide PT 1075 Att. S S & Co. J162987 dt 31/07/1991 Switzerland 15/10/1990 Novartis AG (Novartis SA), Filing Date: (Novartis Inc) Schwarzwaldallee 215, 14/12/1990 Rec Warrant signed on 1076 Hemihydrate Wef: 12/01/1990 Vide PT 1076 Attn: S S & Co. 4058 Basel, Switzerland : J205524 dt 30/09/1991 14/12/1990 Filing Date: 4 Sea Rays Court, Polmer material for Ophthalmic Italtrade Medical Co. Ltd. 27/02/1991 Rec: Warrant signed on 1080 Zonqor Street, Wef: N/A Vide PT 1080 Optical Elements. Attn: N/A J318202 dt 30/09/1991 Marsascala, Malta 27/02/1991 Filing Date: The B.F. Goodrich Company 39225, Embassy Pyridinium Metathesis Catalysts 03/04/1991 Rec: Warrant signed on 1084 Attn: R. Frendo Randon & Parkway, Akron, Ohio Wef: N/A Vide PT 1084 for Cycloolefin Polymerization. J362602 dt 15/10/1991 Associates 4433-1799, U.S.A. 03/04/1991 Tour Maine Filing Date: Montparnasse, 33 Jouveinal S.A 21/06/1991 Warrant signed 1089 Lotion and its preparation. Avenue du Maine, Wef: 26/06/1990 Vide PT 1089 Attn: Mr C. Grech Orr Rec: J396258 dt 30/04/1993 75755 Paris Cedex 15, 21/06/1991 France MT PT No Patent Title Applicant Name Applicant Address MT Filing Date Priority Date Status Abstract Filing Date: Nippon Zeon Co. Ltd. 6-1 Marunouchi 2- Bulk Polymerizable 26/11/1991 Warrant signed on 1101 Attn: R Frendo Randon & chome, Chiyodo-ku, Wef: 28/11/1990 Vide PT 1101 Reaction Solutions Rec: 734408 dt 30/09/1992 Associates Tokyo 100, Japan 26/11/1991 6744 Upper 33rd Street Filing Date: Curing Fluorocarbon Dyneon LLC North, 30/12/1991 Warrant signed on 1104 Wef: 11/01/1991 Vide PT 1104 Elastomers Attn: B&M Patentbureau Oakdale, Minnesota Rec: I734449 dt 28/08/1992 55128, U.S.A. 30/12/1991 25 Sundridge Road, Filing Date: Pharmaceutical Dr.Washington Odur Ayuko Kingstanding, 14/02/1992 Warrant signed on 1106 Wef: 13/02/1991 Vide PT 1106 Composition Attn: B&M Patentbureau Birmingham B44 9NY, Rec: J807684 dt 21/10/1993 Great Britian 13/02/1992 Filing Date: 124 Grenzacherstrasse, Polyethlen-Protein F.Hoffman-La Roche AG 23/03/1992 Warrant signed on 1110 CH-4002 Basel, Wef: 25/03/1991 Vide PT 1110 Conjugates. Att. S S& Co. Rec: I910210 dt 30/09/1992 Switzerland 23/03/1992 A Particular Mineral Salt Filing Date: Composition And a Sunchemie Malta Ltd. 18/1 South Street, 04/09/1992 Warrant signed on 1116 Wef: N/A Vide PT 1116 Process for Making The Attn: S S & Co. Valletta, Malta Rec: K103294 dt 21/10/1993 Same. 11/091992 3M Centre, Saint Paul, Filing Date: Minnesota Mining and Methanol Resistant Minnesota 55144-1000, 03/11/1992 Warrant signed on 1123 Manufacturing Company Wef: 17/12/1991 Vide PT 1123 Fluorocarbon Elastomers U.S.A. Rec: K198614 dt 27/10/1993 Attn: B&M Patentbureau 03/11/1992 P.O Box 1043, Cardinal Filing Date: Quinilone -And- Avenue, Atlantic Industries 07/12/1992 Warrant signed on 1125 Naphthyridone-Carboxyic Georgetown, Grand Wef: 10/01/1992 Vide PT 1125 Attn: S S & Co. Rec: K198723 dt 21/10/1993 Acid Derivatives.
Load more

Recommended publications
  • Sous Forme De Sel De Calcium
    Nom molécule Abamectine Absinthe (teinture de) Acamprosate (sous forme de sel de calcium) Acarbose Acébutolol (sous forme de chlorhydrate) Acéclofénac Acéfylline heptaminol Acémétacine Acépromazine Acépromazine (sous forme de maléate) Acétate de calcium Acétate de magnésium (sous forme de tétrahydrate) Acétate de potassium Acétate de sodium Acétate de sodium (sous forme de trihydrate) Acétazolamide Acétylcholine (sous forme de chlorure) Acétylcystéine Acétylméthionine Acétylméthionine (sous forme de sel de magnésium) Achillée millefeuille Aciclovir Acide acétylsalicylique Acide acétylsalicylique (sous forme de carbasalate de calcium) Acide acétylsalicylique (sous forme de lysinate) Acide acétylsalicylique (sous forme de sel de sodium) Acide adipique Acide alendronique (sous forme de sel de sodium) Acide alginique Acide alginique (sous forme de sel de calcium) Acide aminocaproïque Acide ascorbique Acide ascorbique (sous forme de sel de calcium) Acide ascorbique (sous forme de sel de sodium) Acide aspartique Acide aspartique (sous forme de sel de calcium) Acide aspartique (sous forme de sel de magnésium) Acide aspartique (sous forme de sel de magnésium et de potassium) Acide aspartique (sous forme de sel de magnésium et de potassium dihydraté) Acide aspartique (sous forme de sel de magnésium tétrahydraté) Acide aspartique (sous forme de sel de potassium) Acide aspartique (sous forme de sel de potassium hémihydraté) Acide aspartique (sous forme de zinc) Acide benzoïque Acide benzoïque (sous forme de benzyle) Acide benzoïque (sous forme de
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization II International Bureau (10) International Publication Number (43) International Publication Date WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 513/04 (2006.01) A61P 3/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/542 (2006.01) A61P 25/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB2014/058777 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 4 February 2014 (04.02.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/765,283 15 February 2013 (15.02.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, New York, New York 10017 (US).
    [Show full text]
  • Evaluation of the Efficacy of IQV04 for Weight Loss in Overweight and Obese Dogs
    Evaluation of the efficacy of IQV04 for weight loss in overweight and obese dogs. Annika Bieze 3514870 Supervisor: Dr. R.J. Corbee Abstract Introduction: Overweight and obesity are worldwide problems. Because of the higher risk of associated diseases, it is better to prevent and treat overweight and obesity. Beside weight loss programs, there are different medications and supplements available. After promising results from human health studies on the efficacy of Litramine, a similar product, named IQV04, is developed for dogs to support weight loss. The objective of this study was to evaluate the efficacy of IQV04 for weight loss in overweight and obese dogs. Materials and methods: Nineteen colony dogs were randomly divided in three groups, in this placebo controlled and double-blinded study. All dogs received once a day a standardised maintenance meal for their resting energy requirement (RER) with one of the three pills (IQV04 concentration A, IQV04 concentration B and placebo). Body weight and pelvic circumference were measured weekly. By start and end of the study, physical examination, body condition score, complete blood count, serum biochemical analysis and fecal examination was done. Results: Results suggested that there was a difference in body weight reduction between the three groups. The rate of weight loss in the placebo, IQV04 concentration A and IQV04 concentration B group were 2.45 ± 0.51, 2.85 ± 1.84 and 3.03 ± 1.26% body weight reduction per week, respectively. However, this difference did not reach significance. Also there was no significant difference found in pelvic circumference reduction per week. Conclusion: Further studies with larger patient pool are required to achieve more statistic power.
    [Show full text]
  • Small Animal Formulary 6Th Edition
    BSAVA Small Animal Formulary Ian Ramsey 6th edition Small Animal Formulary 6th edition Editor-in-Chief: Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS Small Animal Hospital, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH Published by: British Small Animal Veterinary Association Woodrow House, 1 Telford Way, Waterwells Business Park, Quedgeley, Gloucester GL2 2AB A Company Limited by Guarantee in England. Registered Company No. 2837793. Registered as a Charity. Copyright © 2008 BSAVA First edition 1994 Second edition 1997 Third edition 1999 Reprinted with corrections 2000 Fourth edition 2002 Reprinted with corrections 2003 Fifth edition 2005 Reprinted with corrections 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder. A catalogue record for this book is available from the British Library. ISBN 978 1 905319 11 4 The publishers and contributors cannot take responsibility for information provided on dosages and methods of application of drugs mentioned in this publication. Details of this kind must be verified by individual users from the appropriate literature. Printed by: HSW Print, Rhondda, Wales. ii BSAVA Small Animal Formulary 6th edition Other titles from BSAVA: Manual of Canine & Feline Abdominal Surgery Manual of Canine & Feline Anaesthesia and Analgesia Manual of Canine & Feline Behavioural Medicine Manual
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/150416 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: sachusetts 02460 (US). FUTATSUGI, Kentaro; 97 West C07D 471/04 (2006.01) A61K 31/519 (2006.01) Main Street, Unit 29, Niantic, Connecticut 06357 (US). C07D 473/32 (2006.01) A61K 31/52 (2006.01) HEPWORTH, David; 282 Sudbury Road, Concord, M as C07D 487/04 (2006.01) A61P 3/10 (2006.01) sachusetts 01742 (US). KUNG, Daniel W.; 289 Laurel- C07D 519/00 (2006.01) wood Drive, Salem, Connecticut 06420 (US). ORR, Suvi; 16 Seabreeze Road, Old Saybrook, Connecticut 06475 (21) International Application Number: (US). WANG, Jian; 164 White Street, Belmont, Mas PCT/IB20 13/052404 sachusetts 02478 (US). (22) International Filing Date: (74) Agents: KLEIMAN, Gabriel L. et al; Pfizer Inc., 235 26 March 2013 (26.03.2013) East 42nd Street, New York, NY 1001 7 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/621,144 6 April 2012 (06.04.2012) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, New York, New York 10017 (US).
    [Show full text]
  • Small Animal Obesity: Effective Control, Management and Care
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk SMALL ANIMAL OBESITY: EFFECTIVE CONTROL, MANAGEMENT AND CARE Author : Catherine F Le Bars Categories : Vets Date : February 23, 2009 Catherine F Le Bars explains how the battle of the bulge and the medical implications specific to certain species need a careful approach to both owner and pet OBESITY is one of the most common nutrition-related conditions in companion animals in the industrialised world, and has a proven association with the development of several disease conditions and reduced longevity. Since weight gain occurs when daily energy intake exceeds energy expenditure, the prevention of obesity requires strict attention to the animal’s nutrition throughout its life. Obesity treatment may be complicated by many factors, and successful management of the condition relies on rigorous owner compliance. Estimates from around the world put the incidence of obesity in dogs and cats at up to 40 per cent, and a number of risk factors have been implicated in its development. These include breed, age, gender, neutering, medication (anti-convulsants, glucocorticoids and contraceptives), lifestyle and exercise, co-existing disease (diabetes mellitus, hypothyroidism, hyperadrenocorticism) and diet. The regulation of food intake is dependent on a complex balance of long-term and shortterm signals to the brain, which are aimed at controlling the fat mass of the animal. When this balance is disrupted, the animal consumes energy above its requirements and gains weight. There are three recognised stages of weight gain: 1 / 10 • A “static ” pre-obesity stage, whereby energy intake is increased but bodyweight remains the same.
    [Show full text]
  • The Comparison of the Effect of Dietary Changes Or Dirlotapide
    THE COMPARISON OF THE EFFECT OF DIETARY CHANGES OR DIRLOTAPIDE TREATMENT ON CANINE OBESITY IN A SMALL ANIMAL VETERINARY PRACTICE A Report of a Senior Study by Anna Elizabeth McRee Major: Biology Maryville College Fall, 2009 Date Approved _____________, by ________________________ Faculty Supervisor Date Approved _____________, by ________________________ Editor ii ABSTRACT One of the greatest clinical challenges in contemporary veterinary medicine is canine obesity, which in the U.S. is increasing similar to trends observed in humans. Obesity impedes the overall wellness of canine patients; it is associated with shorter lifespan in domesticated dogs. The purposes of this study were to evaluate the incidence of obesity in one particular East Tennessee small animal veterinary practice and to examine the efficacy of two readily available treatment tools for this disease: pharmaceutical therapy with dirlotapide or dietary intervention through either caloric restriction or a high fiber diet. The incidence of obesity was examined by recording the body condition score (BCS) on a 1-9 scale for every dog that entered My Pets Animal Hospital for 2 consecutive months during the summer of 2009. Data for 594 dogs was collected in this manner and 4 treatment groups were also evaluated to examine the efficacy of treatment protocols. This study presents two major findings: (1) that 67 % of dogs at this particular veterinary clinic were overweight/obese (based on a BCS score of 6 or greater) and (2) that both dietary changes and pharmaceutical treatment were equally effective at promoting weight reduction in obese canines, as there was no significant difference in the percent weight loss per 30 days (p = 0.969).
    [Show full text]
  • Phytochemicals for Controlling Obesity-Related Cancers
    Crimson Publishers Review Article Wings to the Research Phytochemicals for Controlling Obesity-Related Cancers Madhumita Roy1*and Amitava Datta2 1Department of Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata-700026, India 2Department of Computer Science and Software Engineering, University of Western Australia. 35 Stirling Highway, Perth, WA 6009, Australia ISSN: 2637-773X Abstract Obesity related diseases are on the rise worldwide and obesity is an economic burden on the public health system in most developed and developing countries. The control of obesity is a major challenge that is hard to solve using medication and surgical procedures as those often have serious side effects. Our focus in this article is to highlight the extensive research literature on use of plant-derived chemicals or phytochemicals for control of obesity and obesity related diseases with a particular focus on several types of cancer. We discuss the genes, proteins and pathways involved in obesity and its control, and discuss these genes and pathways. how current research has revealed the beneficial effects of plant-derived chemicals or phytochemicals on Keywords: Obesity; Phytochemicals; Cancer; Adiposity; BMI; Signalling pathways; Genes Introduction *Corresponding author: Madhumita Roy, Department of Environmental Obesity is the state of being overweight, a condition caused due to excessive rate of Carcinogenesis and Toxicology, accumulation and storage of fat in the body. Obesity not only affects appearance, but leads Chittaranjan National Cancer Institute, 37, to a number of health issues. The disparity in calorie consumption and calorie burning leads S. P. Mukherjee Road, Kolkata-700026, to energy imbalance, which is a lead cause of obesity.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]